Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
· bicara therapeutics inc.
AI Briefing
- Phase 3 trial initiated, FORTIFI-HN01 pivotal trial expected to start in mid-2027.
- 1500mg weekly of ficerafusp alfa selected as optimal dose.
- Bicara Therapeutics reports 2025 financial results.
Advertisement